RANKL Predicts 96-Week BMD Changes in ATV/r Monotherapy: A MODAt Trial Sub-Study
Background: To evaluate the association between bone biomarkers and changes in bone mineral density (BMD) over 96 weeks in patients treated with atazanavir/ritonavir (ATV/r) monotherapy vs ATV/r+2 N(t)RTIs. Methods: MODAt (NCT01511809) is a multicentric, randomized, open-label, non-inferiority trial. Patients on ATV/r 300/100mg+2 N(t)RTIs since≥48 weeks, virologically suppressed since≥24 weeks, randomized to ATV/r monotherapy (arm A)…